Drug-coated balloons for coronary and peripheral interventional procedures

Current Cardiology Reports

Volumn 14, Issue 5, 2012, Pages 635-641

  Wöhrle, Jochen ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Bare metal stents; Below the knee; Chronic total occlusion; Coronary and peripheral interventional procedures; De novo lesion; Drug coated balloon; Drug eluting balloon; Drugeluting stents; Dual antiplatelet therapy; Femoropopliteal; In stent restenosis; Late loss; Paclitaxel; Paclitaxel coated balloon; Paclitaxel eluting balloon; Stent thrombosis; Target lesion revascularization; Thrombotic event

Indexed keywords

IOPROMIDE; PACLITAXEL;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BALLOON CATHETER; BARE METAL STENT; BLOOD VESSEL OCCLUSION; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; DRUG COATED BALLOON; DRUG ELUTING STENT; ENDOTHELIAL PROGENITOR CELL; FEMOROPOPLITEAL ARTERY; HUMAN; INTERMETHOD COMPARISON; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPLITEAL ARTERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; TARGET LESION REVASCULARIZATION; TREATMENT DURATION;

ANGIOPLASTY, BALLOON; ANGIOPLASTY, BALLOON, CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PACLITAXEL; STENTS; TREATMENT OUTCOME;

EID: 84870600008     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0290-x     Document Type: Article

References (56)

1. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104:600-5. (Pubitemid 32738132)
2. Cremers B, Speck U, Kaufels N, et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101:201-6.
3. Scheller B, Hehrlein C, Bocksch W, Mahnkopf D, Kühler M, Böhm M, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-24. (Pubitemid 44749319)
4. Wöhrle J, Birkemeyer R, Markovic S, Nguyen TV, Sinha A, Miljak T, et al. Prospective randomized trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart. 2011, 97:1338-42.
5. Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES Study. J Am Coll Cardiol. 2012;59:1377-82.
6. Wöhrle J, Werner GS. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. Catheter Cardiovasc Interv. 2012;doi:10. 1002/ccd. 24409, in press.
7. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810-4. (Pubitemid 39096008)
8. Kelsch B, Scheller B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, et al. Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest Radiol. 2011;46:255-63.
9. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
10. Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, et al. Comparison of everolimus-and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (a clinical evaluation of the XIENCE Veverolimus eluting coronary stent system) and COMPARE (a trial of everolimuseluting stents and paclitaxel-eluting stents for coronary revascularization in daily practice) Trials. JACC Cardiovasc Interv. 2011;4:1104-15.
11. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and baremetal stents: evidence from a comprehensive network metaanalysis. Lancet. 2012;379:1393-402.
12. Wöhrle J, Rottbauer W, Imhof A. Everolimus-eluting stents for treatment of chronic total coronary occlusions. Clin Res Cardiol. 2012;101:23-8.
13. Cremers B, Biedermann M, Mahnkopf D, Böhm M, Scheller B. Comparison of 2 different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2009;98:325-30.
14. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, et al. Sirolimus-eluting vs bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-8. (Pubitemid 40354849)
15. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: 6 month results. Circulation. 2002;106:1505-9.
16. Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:149-54.
17. Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a Paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5:323-30.
18. Wöhrle J, Zadura M, Möbius-Winkler S, et al. SeQuent Please World Wide Registry: Clinical results of SeQuent Please paclitaxel coated balloon angioplasty in a large-scaled, prospective registry study. J Am Coll Cardiol. 2012, (in press).
19. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter vs paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986-94.
20. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006;95:1253-63.
21. Ellis SG, O'Shaughnessy CD, Martin SL, Kent K, McGarry T, Turco MA, et al. Two-year clinical outcomes after paclitaxeleluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J. 2008;29:1625-34. (Pubitemid 351958446)
22. Kleber FX, Mathey DG, Rittger H, Scheller B. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011;Suppl K:K125-8.
23. Cremers B, Clever Y, Schaffner S, Speck U, Böhm M, Scheller B. Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. Minerva Cardioangiol. 2010;58:583-8.
24. Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, et al. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroIntervention. 2011;7:705-10.
25. Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2010;99:165-74.
26. Ali RM, Degenhardt R, Zambahari R, Tresukosol D, Ahmad WA, Kamar HH, et al. Paclitaxel-eluting balloon angioplasty and cobaltchromium stents vs conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention. 2011;7 Suppl K:K83-92.
27. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol. 2005;45:1574-9. (Pubitemid 40704488)
28. Duckers HJ, Silber S, deWinter R, den Heijer P, Rensing B, Rau M, et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention. 2007;3:67-75.
29. Beijk MA, Klomp M, Verouden NJ, van Geloven N, Koch KT, Henriques JP, et al. Genous endothelial progenitor cell capturing stent vs the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J. 2010;31:1055-64.
30. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215-23. (Pubitemid 41352109)
31. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31. (Pubitemid 38067635)
32. Werner GS, Krack A, Schwarz G, Prochnau D, Betge S, Figulla HR. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol. 2004;44:2301-6. (Pubitemid 39647602)
33. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006;114:921-8. (Pubitemid 44337135)
34. Werner GS, Ferrari M, Fritzenwanger M, Betge S, Figulla HR. Long-term safety and efficacy of paclitaxel-eluting stents in chronic total coronary occlusions: 3 year follow-up from the paclitaxel in chronic total occlusion (PACTO) study. Eur Heart J. 2007;28 (Abstract):135.
35. Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, et al. Paclitaxel-coated balloon vs drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010;96:1291-6.
36. Belkacemi A, Agostoni P, Nathoe HM, VoskuilM, Shao C, Van Belle E, et al. First results of the DEB-AMI (drug eluting balloon in acute stsegment elevation myocardial infarction) Trial: Amulticenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol. 2012; in press.
37. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81-157.
38. Beschorner U, Sixt S, Schwarzwälder U, Rastan A, Mayer C, Noory E, et al. Recanalization of chronic occlusions of the superficial femoral artery using the Outback re-entry catheter: a single centre experience. Catheter Cardiovasc Interv. 2009;74:934-8.
39. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty vs implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-88. (Pubitemid 43872689)
40. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation vs balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: 3-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1-9.
41. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-9. (Pubitemid 46842791)
42. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, et al. Balloon angioplasty vs stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74:1090-5.
43. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851-906.
44. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi J, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-99. (Pubitemid 351240748)
45. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: 12-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504.
46. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: 12-month safety and effectiveness results from the Zilver PTX singlearm clinical study. J Endovasc Ther. 2011;18:613-23.
47. Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, et al. Clinical evaluation of a Paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter italian registry. JACC Cardiovasc Interv. 2012;5:331-8.
48. Zeller T, Rastan A, Sixt S, Schwarzwälder U, Schwarz T, Frank U, et al. Long-term results after directional atherectomy of femoropopliteal lesions. J Am Coll Cardiol. 2006;48:1573-8. (Pubitemid 44528188)
49. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23.
50. Karnabatidis D, Spiliopoulos S, Diamantopoulos A, Katsanos K, Kagadis GC, Kakkos S, et al. Primary everolimus-eluting stenting vs balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. J Endovasc Ther. 2011;18:1-12.
51. Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Kraniotis P, Diamantopoulos A, et al. Sirolimus-eluting vs bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther. 2007;14:241-50. (Pubitemid 46776123)
52. Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, et al. Randomized comparison of everolimus-eluting vs bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390-8.
53. Lookstein R, Ward T, Kim E, Fischman A, Nowakowksi F, Ellozy S, et al. Value of drug-eluting stents after failed percutaneous transluminal angioplasty in the infrapopliteal vessels for the treatment of critical limb ischemia: favorable mid-term patency and limb salvage results. J Cardiovasc Surg. 2011;52:461-6.
54. Biondi-Zoccai GG, Sangiorgi G, Lotrionte M, Feiring A, Commeau P, Fusaro M, et al. Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients. J Endovasc Ther. 2009;16:251-60.
55. Rastan A, Noory E, Zeller T. Drug-eluting stents for treatment of focal infrapopliteal lesions. Vasa. 2012;41:90-5.
56. Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y, Bräunlich S, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105-9.